scholarly journals Pulmonary Rehabilitation is Improved by In-Shoe Foot Orthosis Intervention

2020 ◽  
pp. 41-47
Author(s):  
Yves Jammes ◽  
Hanan Rkain ◽  
Jean Paul Weber ◽  
Patricia Griffon ◽  
Bruno Vie ◽  
...  
Keyword(s):  
Pulmonary Rehabilitation ◽  
Plantar Flexion ◽  
Controlled Study ◽  
Chronic Obstructive ◽  
Foot Orthoses ◽  
Obstructive Pulmonary Disease ◽  
6Mwt Distance ◽  
Group 2 ◽  
Foot Orthosis ◽  
Group 1

Some studies have found that patients with asthma have bilateral foot dorsal flexion limitations, contributing to impaired quality of life. The authors hypothesised that foot misalignments could also occur in patients with chronic obstructive pulmonary disease (COPD), and that foot orthoses could increase the motor benefits of their pulmonary rehabilitation (PR). Presented herein are the results from a nonrandomised controlled study in 40 patients with COPD. Twenty patients had foot misalignment (Group 1) and wore foot orthoses for a 1-month PR period. Their data were compared to those obtained in 20 other patients with COPD who had no foot misalignment and did not wear foot orthoses (Group 2). Bodily fatigue, 6-minute walk test (6MWT) distance, peak plantar flexion force (PFF), and oscillations of the centre of pressure (CoP) were measured. Measurements were performed prior to and following completion of PR (Groups 1 and 2), immediately after wearing the foot orthosis (Group 1), and after completion of PR plus foot orthoses (Group 1). In Group 2, PR increased the 6MWT distance, but did not increase PFF nor reduce CoP oscillations and fatigue scale. Wearing the foot orthosis for the first time significantly increased the 6MWT distance (+98+12 m). Following PR with foot orthoses (Group 1), a further increase in 6MWT distance occurred (+120+13 m), bodily fatigue was reduced, PFF increased, and CoP oscillations decreased. In patients with COPD and foot misalignment, foot orthoses enhanced the functional capacity and improved the postural control.

scholarly journals Twice versus three-times weekly pulmonary rehabilitation in a real-life clinical setting

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 89
Author(s):  
Keir Lewis ◽  
Lucy Thatcher ◽  
Carol-Anne Davies ◽  
Patricia Hodgson ◽  
Carol Llewellyn-Jones ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Pulmonary Rehabilitation ◽  
Real Life ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
St George's Respiratory Questionnaire ◽  
Observational Cohort ◽  
Group 2 ◽  
Hospital Days ◽  
Group 1

Aim: Our aim was to compare a less intensive but longer pulmonary rehabilitation programme (PRP) against a more intensive but shorter PRP.Methods: We carried out an observational, cohort study in a real-life clinical setting in patients primarily with chronic obstructive pulmonary disease (COPD). We compared standard outcomes in patients who were receiving 18 sessions of PRP delivered twice weekly over 9 weeks (Group 1) against similar patients receiving an identical PRP delivered three times weekly over 6 weeks (Group 2). Outcome measures were the St. George’s Respiratory Questionnaire (SGRQ), the Incremental Shuttle Walk Test (ISWT) and the number of hospital bed-days pre- and post-PRP.Results: Both groups showed statistically significant and clinically important improvements post-PRP. The largest effects were seen immediately post-PRP and waned over the following 12 months. Group 1 showed a larger improvement in ISWT immediately post-PRP (Group 1, +92 m versus Group 2 +64 m (p=0.001), but there were no differences between groups at 6 (p=0.67) or 12 months (p=0.96). There were no differences in SGRQ between groups immediately post-PRP (p=0.09) or at 12 months (p=0.78). There were no differences between groups in the number of hospital days 12 months prior to PRP versus 12 months post-PRP (p=0.18).Conclusion: Twice weekly outpatient, multidisciplinary PRP over 9 weeks is as effective as three times weekly PRP over 6 weeks.

scholarly journals THE EFFECT OF TRACHEAL DIVERTICULUM AND CHRONIC OSTRUCTIVE LUNG DISEASE ON CHEST ANTHROPOMETRY

2021 ◽  
Author(s):  
Mine ARGALI DENIZ ◽  
Hilal ER ULUBABA ◽  
M. Furkan ARPACI ◽  
Fatih CAVUS ◽  
Gokhan DEMIRTAS ◽  
...  
Keyword(s):  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Group 4 ◽  
Tracheal Diverticulum ◽  
Copd Patients ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Objective: In this study, the effect of tracheal diverticula (TD) on chest anthropometry and its relation with chronic obstructive pulmonary disease (COPD) was evaluated. Method: Between January 2019 and March 2020, 995 patients who underwent chest CT were retrospectively analyzed and TD was detected in 31 cases. Group 1 is only TD, Group 2 is TD + COPD, Group 3 is only COPD, Group 4 is defined as control group. We measured the localization, size, the distance to carina and vocal cord of TDs. In all groups chest diameters at T4 and T9 levels were measured as transverse and vertical plans. Results: TDs detected mostly at the T2 and T3 levels. In Group 1 and Group 2, there was a statistically significant difference the distance to TD of vocal chords. A statistically significant difference was found between Group 1 and Group 3 only in the vertical diameter at the T4 and T9 levels. Conclusion: We observed that COPD effect TD location and also TD had opposite effect on anteroposteriorly increasing chest parameters in COPD. Precence of TD is essential on COPD patients about thorax anthropometry. Keywords: Tracheal diverticulum; antropometry; radiology; COPD; chest diameter

scholarly journals Features of the Functional Status and Cytokine Profile of Patients with Chronic Heart Failure in Combination with Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 11 (1) ◽  
pp. 9-13
Author(s):  
Roman Tokmachev ◽  
Andrey Kravchenko ◽  
Andrey Budnevsky ◽  
Evgeniy Ovsyannikov ◽  
Evgeniy Tokmachev ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Functional Status ◽  
Serum Levels ◽  
Cytokine Profile ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Group 2 ◽  
Hs Crp ◽  
Group 1

The purpose of this research was to study the effect of COPD on the functional status and cytokine profile of patients with chronic heart failure (CHF) with different ejection fraction (EF). Methods and Results: The study involved 240 patients diagnosed with CHF (mean age of 72.4±8.7 years). Among them, 80 patients were diagnosed with CHF and COPD. Depending on the presence of COPD, the patients were divided into two groups: Group 1 included 160 patients with CHF without COPD; Group 2 included CHF 80 patients with COPD. According to the value of LVEF, each of the two groups was divided into two more subgroups: In Group 1, CHFpEF (EF≥50%) was recorded in 69 patients (Subgroup 1) and CHFrFV (EF<50%) in 91 patients (Subgroup 2). In Group 2, CHFpEF was observed in 36 patients (Subgroup 3) and CHFrEF in 44 patients (Subgroup 4). The 6-minute walk distance (6MWD) was measured in meters and compared with the proper 6MWD(i). All patients included in the study underwent the Borg test to assess dyspnea after 6MWT. The serum levels of NT-proBNP, hs-CRP, IL-1β, IL-6, and TNF-α were determined using an automatic analyzer IMMULITE 2000 (Siemens Diagnostics, USA) and quantitative ELISA kits. The patients with CHFpEF had higher levels of hs-CRP, pro-inflammatory cytokines than patients with CHFrEF. The combination of COPD and CHF amplifies systemic inflammation (hs-CRP, proinflammatory cytokines) and myocardial remodeling processes (NT-proBNP) in comparison with the isolated course of CHF. COPD negatively affects the functional status of patients with CHF with different EF by lower values of 6MWD, 6MWD/6MWD(i) ratio, and higher results on the Borg dyspnea test.

scholarly journals How to improve the effectiveness of combination therapy of arterial hypertension in patients with concomitant chronic obstructive pulmonary disease?

2020 ◽  
Vol 4 (7) ◽  
pp. 418-424
Author(s):  
N.Yu. Grigorieva ◽  
◽  
M.O. Samolyuk ◽  
T.V. Sheshina ◽  
N.B. Koroleva ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lipid Peroxidation ◽  
Arterial Hypertension ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Number Of Patients ◽  
Group 2 ◽  
Azilsartan Medoxomil ◽  
Group 1

Aim: to conduct a comparative assessment of the hypotensive effect, as well as the effect on endothelial function, oxidative stress, and pulmonary artery pressure of chlorthalidone and hydrochlorothiazide as part of combined antihypertensive therapy in patients with arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD).Patients and Methods: the prospective study included 66 patients divided into two groups. As the main antihypertensive therapy, group 1 was prescribed with a combination of azilsartan medoxomil 40 mg and chlortalidone 12.5 mg as a fixed combination of Edarbi® CLO. Group 2 received a free combination of azilsartan medoxomil 40 mg (Edarbi®) and hydrochlorothiazide 12.5 mg. All patients underwent 24-hour blood pressure monitoring: (ABPM), echodopplercardiography, endothelium-dependent vasodilation, lipid peroxidation (LPO), nitric oxide metabolites, and endothelin-1 levels at baseline and after 6 months of treatment. Results: target blood pressure values (<130/80 mm Hg) were achieved in 91% of patients in group 1, and 51.5% in group 2 after 1 month of the study. After 6 months of treatment, all patients in both groups reached the target BP values, but in group 2, the dose of hydrochlorothiazide had to be increased to 25 mg. According to the ABPM data, after 6 months of treatment, group 1 showed a decrease in the morning surge in SBP by 7.0±2.1% and DBP by 10±7.3%. There was also an increase in the number of patients with the daily profile of «dipper» type to 78.8%. In group 2, there was a decrease in the morning surge in SBP by 6.3±5.9% and DBP by 4.8±4.6% after 6 months of treatment. There was an increase in the number of patients with the daily profile of «dipper» type to 36.4%. After 6 months of treatment, there was more pronounced improvement in laboratory parameters of group 1 characterizing endothelial dysfunction and oxidative stress. Statistically significant results were obtained for conjugated trienes, NO2, S, Imax, and endothelin-1 when comparing groups 1 and 2.Conclusion: treatment of AH in patients with concomitant COPD in the form of a fixed combination of azilsartan medoxomil and chlorthalidone versus free combination of azilsartan medoxomil with hydrochlorothiazide has a more pronounced antihypertensive effect, positively affecting the daily BP profile, pulmonary artery pressure, endothelial function and lipid peroxidation processes after 6 months of treatment.KEYWORDS: arterial hypertension, chronic obstructive pulmonary disease, endothelial dysfunction, lipid peroxidation, azilsartan medoxomil, chlorthalidone.FOR CITATION: Grigorieva N.Yu., Samolyuk M.O., Sheshina T.V. et al. How to improve the effectiveness of combination therapy of arterial hypertension in patients with concomitant chronic obstructive pulmonary disease? Russian Medical Inquiry. 2020;4(7):418–424. DOI: 10.32364/2587-6821-2020-4-7-418-424.

scholarly journals 699 Incidence of COPD in primary and secondary outcomes in patients undergoing a TAVI

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Elie Alkhoury ◽  
Francesca Romana Prandi ◽  
Giulia Pensabene ◽  
Marco Di Luozzo ◽  
Massimo Marchei ◽  
...  
Keyword(s):  
Hospital Mortality ◽  
Medical Treatment ◽  
Hospital Stay ◽  
Severe Aortic Stenosis ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
The Mean ◽  
Group 2 ◽  
Severe Copd ◽  
Group 1

Abstract Aims The association between severe chronic obstructive pulmonary disease (COPD) and in-hospital mortality (IHM) as well as incidence of post-procedural intubation and length of in-hospital stay (LOHS) in patients with severe aortic stenosis (AS) undergoing transfemoral (TF) transcatheter aortic valve implantation (TAVI) is still unclear. We evaluated the impact of severe COPD on IHM, post-procedural tracheal intubation and LOHS in patients with severe AS undergoing TF TAVI. Methods We retrospectively analysed a total of 550 consecutive patients who underwent transfemoral TAVI in our centre between 2011 and 2021. We divided the patients in Group 1 (affected by severe COPD) and Group 2 (without COPD). We further divided the patients affected by COPD into Subgroup A (on COPD medical treatment) and Subgroup B (without COPD medical treatment). Results A total of 550 patients who underwent TF TAVI were included in this analysis. 38.55% (n=212) had a diagnosis of COPD (Group 1) and 61.45% (n=338) were not affected by COPD (Group 2). In Group 1, 29.38% (n=62) of patients were receiving medical treatment for COPD (Subgroup A), while 70.6% (n=149) were not on COPD medications (Subgroup B). The mean age was 81.83±6.67 in Group 1 vs. 81.33±7.21 in Group 2 (P=0.45), and 82.12±7.6 in Subgroup A vs. 82.14±6.82 in Subgroup B (P=0.98). The gender distribution showed 127 (45%) men in Group 1 vs. 96 (50%) men in Group 2 (P=0. 33), and 21 (42%) men in Subgroup 1 vs. 75 (53%) men in Subgroup B (P=0.28). The mean EUROSCOREII was 8.26±7.03 in Group 1 vs. 6.81± 7.57 in Group 2, P= 0.11, and 7.24±5.49 in Subgroup A vs. 9.30±7.5 in Subgroup B, P=0.52. There was no difference observed for in-hospital mortality between Group 1 and Group 2 (0.04% vs. 0.05%; P=0.6) and between Subgroup A and Subgroup B (0.04% vs. 0.04%; P=0.7). Similarly, the incidence of post-procedural intubation was comparable between Group 1 and Group 2 (0.06% vs. 0.03%; P=0.18), and between Subgroup A and Subgroup B (0.08% vs. 0.05%; P=0.78). Finally, also the mean length of in-hospital stay was similar between Group 1 and Group 2 (10±4.46 days vs. 9.68± 5.02 days; P=0.47), and between Subgroup A and Subgroup B (10.36±4.24 days vs. 9.87±4.54 days; P=0.5). Conclusions In patients with severe aortic stenosis treated with transfemoral TAVI, the presence of severe COPD does not affect in-hospital mortality, incidence of post-procedural intubation and length of in-hospital stay. COPD medications do not impact any of the outcomes evaluated. Therefore, TF TAVI is a safe procedure also for patients affected by severe chronic obstructive pulmonary disease that are not on COPD medications.

scholarly journals Is Chronic Obstructive Pulmonary Disease An Independent Risk Factor For Coronary and Peripheral Atherosclerosis In Heavy Smokers?

2020 ◽  
Author(s):  
Maria Angélica Pires Ferreira ◽  
Leila Beltrami Moreira ◽  
Felipe Soares Torres ◽  
Marli Maria Knorst
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Similar Distribution ◽  
Obstructive Pulmonary Disease ◽  
The Mean ◽  
Group 2 ◽  
Heavy Smokers ◽  
Group 1

Abstract BACKGROUNDThere is a high prevalence of cardiovascular disease (CVD) and atherosclerosis in people with chronic obstructive pulmonary disease (COPD); sharing of risk factors could not be the only cause of the association.OBJECTIVESTo verify whether coronary atherosclerosis and peripheral vascular disease are independently associated with COPD in heavy smokers. We also investigated whether inflammation and poor lung function were related with atherosclerosis findings.METHODSHeavy smokers (≥ 20 pack-years) with COPD (group 1) or normal spirometry (group 2) were recruited. Clinical, laboratory, and anthropometric data were obtained. Main interest variables were prevalence of CCS > 75th percentile (P75), and rates of ABI < 0,9 by Doppler ultrasound. CVD risk was calculated using the Framingham risk score. Serum C-reactive protein (CRP) was measured, and lung function was assessed by spirometry. Differences between groups were compared using parametric and nonparametric tests as adequate.RESULTSWere included 87 patients, 49 with COPD (group 1). The mean ± SD age was 57.2 ± 6.0 years (58.7 ± 5.1 in group 1, 55.2 ± 6.6 in group 2, p=0.006). The mean FEV 1 % was 45.8 ± 17.24 vs. 91.7 ± 15.9 in groups 1 and 2, respectively; p<0.05. The mean smoking index was 48.6 ± 25.4, higher in the COPD group (p=0.037). Stratification by Framingham score yielded a similar distribution in both groups. The frequency of patients with CCS > P75 was 55% vs. 66% in groups 1 and 2, respectively (p=0.823); ABI <9.0 ocurred in 6,3% vs 2,6%, respectivelly ( p=0.555) . CCS and ABI were not associated to FEV 1 %. CRP was inversely associated with VEF 1 ( r s= -0.419; p<0.001), but unrelated to CCS ( r s= 0.136; p=0.265) and ABI ( r s= -0.51; p=0.677).CONCLUSIONSThe studied coronary and peripheral atherosclerosis markers were similar between heavy smokers with COPD and those with normal spirometry. Nor serum CRP neither poor lung function related to CCS or ABI. Our results suggest absence of a independent association between COPD and atherosclerosis.

scholarly journals Survival Impact of Chronic Obstructive Pulmonary Disease or Acute Exacerbation on Patients with Rectal Adenocarcinoma Undergoing Curative Resection: A Propensity Score-Matched, Population-Based Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4221
Author(s):  
Jiaqiang Zhang ◽  
Kuo-Chin Chiu ◽  
Wei-Chun Lin ◽  
Szu-Yuan Wu
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Overall Survival ◽  
Curative Resection ◽  
Rectal Adenocarcinoma ◽  
Survival Outcomes ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
All Cause Mortality ◽  
Group 2 ◽  
Group 1

Purpose: The survival effect of current smoking-related chronic obstructive pulmonary disease (COPD) and COPD with acute exacerbation (COPDAE) is unclear for patients with rectal adenocarcinoma undergoing curative resection. Methods: We recruited patients with clinical stage I–IIIC rectal adenocarcinoma from the Taiwan Cancer Registry Database who had received surgery. The Cox proportional hazards model was used to analyze all-cause mortality. We categorized the patients into two groups by using propensity score matching based on COPD status to compare overall survival outcomes: Group 1 (current smokers with COPD) and Group 2 (nonsmokers without COPD). Results: In the multivariate Cox regression analyses, the adjusted hazard ratio (aHR; 95% confidence interval (CI)) of all-cause mortality for Group 1 compared with Group 2 was 1.25 (1.04–1.51). The aHRs (95% cis) of all-cause mortality for frequency of ≥1 hospitalizations for COPDAE or ≥2 hospitalizations within 1 year before diagnosis were 1.17 (1.05–1.51) and 1.48 (1.03–2.41) compared with no COPDAE in patients with rectal adenocarcinoma undergoing curative resection. Conclusion: In patients with rectal adenocarcinoma undergoing curative resection, being a current smoker with COPD (Group 1) was associated with worse survival outcomes than being a nonsmoker without COPD (Group 2). Being hospitalized at least once for COPDAE within 1 year before the diagnosis of rectal adenocarcinoma is an independent risk factor for poor overall survival in these patients, and a higher number of hospitalizations for COPDAE within 1 year before diagnosis was associated with poorer survival.

scholarly journals The effect of comorbidity severity on pulmonary rehabilitation outcomes in chronic obstructive pulmonary disease patients

2018 ◽  
Vol 16 ◽  
pp. 147997231880947
Author(s):  
Ilknur Naz ◽  
Hulya Sahin ◽  
Yelda Varol ◽  
Berna Kömürcüoğlu
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Pulmonary Rehabilitation ◽  
Pulmonary Function Tests ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Group 2

Chronic obstructive pulmonary disease (COPD) is not only associated with respiratory system involvement but also with systemic consequences leading to chronic comorbidities. In this study, we aimed to investigate the effect of comorbidity severity on pulmonary rehabilitation (PR) outcomes in COPD patients. We conducted a retrospective cohort study to compare the effectiveness of PR in COPD patients who completed an 8-week PR program. There were at least one comorbid in 120 of 211 patients and we divided them into the groups according to Charlson Comorbidity Index (CCI) scores (1 points, group 1 ( n = 54); 2 points, group 2 ( n = 41); 3 points, group 3 ( n = 25)). We compared 6-minute walk distance (MWD), dyspnea perception, pulmonary function tests, blood gases analysis, quality of life, anxiety, and depression scores which were recorded before and after PR between the groups. Before PR 6-MWD distance was significantly lower in group 2 ( p = 0.033). Improvements in 6-MWD, blood gas values, dyspnea perception, quality of life, and anxiety were determined in all groups after PR ( p < 0.05). When the gains after PR were compared, there were no significant differences between groups ( p > 0.05). COPD patients benefit from PR independent from their comorbidity severity. Comorbidity severity has no effect on PR gains. Therefore, patients with comorbidities should not be excluded from PR programs and encouraged to participate. Clinical Trial Number: NCT03319108.

Sign in / Sign up

Export Citation Format

Share Document